Europe Pulmonary Arterial Hypertension Market Outlook

pulmonary arterial hypertension (pah) is a rare disease of the lungs, in which the blood vessels that transport blood from the heart to the air sacs of the lungs become unusually narrow or blocked. upper and lower part of the lungs are most seriously affected by this medical condition. pah restricts the flow across the lungs, causing elevation of the pressure within the pulmonary arteries and thus resulting in overall physiological deterioration. numerous therapies have been developed in recent years to prevent, treat and ameliorate the degree of morbidity in pah patients. europe is a major market for pulmonary arterial hypertension drugs as it has huge patient pool and comparably strong healthcare infrastructure. an increase in the incidence rate of clinical and undiagnosed pah cases due to rising lifestyle-related complications is widely observed across the region. also, the increasing populace of aged and geriatric individuals is creating a surge in the number of pah cases. this will, in turn, drive the market for a range of pah therapeutics during the forecast period. the key player dominating the europe pulmonary arterial hypertension market include actelion pharmaceuticals, teva pharmaceuticals, uptravi, bayer ag, glaxosmithkline plc, lung therapeutics, free mind group and others. these players are focusing more on launching new therapies and engaging in frequent research & development activities. it becomes vital for the pharmaceutical companies to keep innovating their products in order to ensure strong market presence across the europe market. however, a high cost associated with the therapies and unsustainable pricing strategies along with an unclear reimbursement framework in pah area are proving to be the major restraints for eu pah therapeutics market. furthermore, it is very difficult for large pharmaceutical companies to launch their products in the europe market even after a successful completion of clinical trials due to strict guidelines present within the political and legal frameworks. it is not easy for the smaller companies to compete against the larger players due to their well-established infrastructure. overall, the europe pulmonary arterial hypertension market is expected to show a healthy growth rate in the upcoming years due to increasing prevalence of the disease, growing elderly population, and presence of established therapeutics and drug pipelines. several countries are also working on healthcare reform and making medical services accessible to more patients. this is likely to result in increased demand for pah therapeutics from europe over the forecast period (2018-2032).